Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery

NCT ID: NCT00355563

Last Updated: 2009-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study has been designed to comparatively evaluate the safety and effectiveness of the PAS-Port Proximal Anastomosis System and conventional suturing techniques for creation of the connection between graft veins and the aorta in patients undergoing coronary artery bypass graft surgery for treatment of coronary artery disease. Patients in the study will have a coronary angiogram approximately 9 months following surgery to determine the patency of vein grafts created using either the automated PAS-Port or hand sewn methods. Safety will be evaluated by documenting the occurence of adverse clinical events and evealuating possible association with either method.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PAS-Port Automated Proximal Anastomosis System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give informed consent, able to understand the intent and clinical meaning of the study as well as its implications. Patient is legally competent.
* Assessment that the patient is willing and able to have follow-up visits and examinations
* Age greater than or equal to 50 years and less than 85 years
* Ejection fraction of \>30%
* Can tolerate radiographic contrast media
* Requires non-emergent coronary artery bypass with at least two vein bypass grafts intended
* Coronary artery targets intended for bypass index grafts must have \>70% native stenosis
* Life expectancy \>1 year


* Patient is hemodynamically stable
* Open chest reassessment of the revascularization strategy confirms that two vein bypass grafts are still intended
* Target vessel wall properties that are suitable for performing both a hand-sewn and a PAS-Port anastomosis
* Target vessel is greater than 1.8 mm in diameter at sites where anastomoses are planned
* Target vessel at sites where anastomoses will be placed are free from severe calcifications or severe atheromas
* The length of the vein graft(s) is adequate for both of the planned index graft revascularization strategies
* Vein outside diameter and double wall thickness are between 4 and 6 mm(inclusive) and less than or equal to 1.4 mm, respectively, at the graft site intended for the PAS-Port proximal anastomosis
* The vein(s) is of suitable quality to be used as a bypass graft conduit

Exclusion Criteria

* Patient is participating in other clinical trials that would conflict with this protocol
* Unable to meet study requirements (travel, general health)
* Pregnancy
* Previous cardiac surgery
* Requiring preoperative use of an intraaortic balloon pump
* Congestive heart failure / NYHA Class IV
* History of thromboembolic disease requiring ongoing anticoagulation therapy or the presence of a bleeding disorder
* Acute or chronic dialysis
* Creatinine of greater than 200 µmol/L (2.3 mg/dL) in the last 30 days
* Documented acute or suspected systemic infection
* Need for ongoing immunosuppressive therapy
* Recent (less than 2 weeks) history of cerebrovascular accident
* Aspirin allergy or other contraindications to aspirin use

INTRA-OPERATIVELY
Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardica, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cardica, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Puskas, M.D.

Role: PRINCIPAL_INVESTIGATOR

Emory University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Michael's Medical Center

Newark, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IP2005-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Initial Evaluation of Vascudyne Coronary Artery Bypass Conduit
NCT06434935 ENROLLING_BY_INVITATION EARLY_PHASE1
CABG Without the Use of CPB
NCT00202332 COMPLETED PHASE2
Impella Supported OPCABG
NCT04339452 ACTIVE_NOT_RECRUITING